Context: One in 4 men in the United States aged Ͼ50 years will have an osteoporosis-related fracture. Fewer data are available on osteoporosis treatment in men than in women.
T he health burden of osteoporosis in men is expected to increase with an aging population and increasing life expectancy. One in 4 men in the United Stated aged Ͼ50 years will have a fracture due to osteoporosis (1) . Both hip and vertebral fractures are associated with increased morbidity and mortality in men (2) , and at any given age, mortality after hip fracture is higher in men than in women (3) . Whereas the risk of osteoporosis-related fractures has been extensively studied for women, fewer published data for men are available.
There are a number of approved treatments for osteoporosis in men. The most commonly used are bisphosphonates. Oral bisphosphonates require long-term daily, once weekly, or once monthly dosing, with persistence and compliance waning as the treatment continues (4) . Zoledronic acid is administered as a once yearly intravenous infusion (5) . Whereas this assures that the patient is treated for at least 1 year, an infusion in a primary care setting may not always be feasible for patients, and other challenges may include iv access, infusion reactions, and the potential for renal compromise (5) . Teriparatide (parathyroid hormone) is administered daily by self-injection, which can be inconvenient for patients (6) .
Denosumab is a fully human monoclonal IgG 2 antibody that binds to RANKL. In women with postmenopausal osteoporosis, denosumab markedly reduced bone resorption, increased bone mineral density (BMD), and significantly reduced the risk of new vertebral and nonvertebral fractures, including hip fractures (7) . Denosumab is approved in several countries as a treatment to increase bone mass in men with osteoporosis at high/increased risk for fracture (7) . A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of denosumab vs placebo in males with osteoporosis (ADAMO) was undertaken to further define the response to therapy. The study comprised 2 consecutive 12-month phases. In the first 12 months, the study was double-blind and placebo-controlled and reported that denosumab therapy reduced bone resorption, increased BMD at all skeletal sites assessed, and was well tolerated (8) . We now report the results from the second year of the ADAMO study, in which all patients were to receive open-label denosumab for 12 months.
Subjects and Methods

Study design
A multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial of men with low BMD was conducted at 27 study centers in Belgium, Canada, Denmark, France, Poland, Sweden, and the United States. The study comprised 2 12-month phases. The first 12-month phase was a double-blind, randomized trial comparing 60 mg of denosumab sc every 6 months (q6m) with placebo ( Figure 1 ). At month 12, men entered the second phase. In this open-label phase, all participants (independent of randomization) were to receive 60 mg of denosumab sc q6m at months 12 and month 18. All participants were required to take daily supplements of Ն1000 mg elemental calcium and Ն800 IU vitamin D during the study. The study protocol was approved by an institutional review board or ethics committee for each site. All participants provided written informed consent.
The endpoints for the first phase of the study have been reported previously (8) . The endpoints for the open-label phase (through month 24) were exploratory (percent changes in BMD of the lumbar spine, total hip, femoral neck, trochanter, and 1/3 radius and the percent change from baseline in serum type I collagen C-telopeptide [sCTX]) and safety. Safety was evaluated as crude and exposure-adjusted participant incidence of adverse events (AEs).
Participants
Participants enrolled in the ADAMO trial were ambulatory men between the ages of 30 and 85 years. Details on the inclusion and exclusion criteria have been previously published (8) . In brief, men were considered eligible if they had a T-score (based on male reference ranges) of ՅϪ2.0 and ՆϪ3.5 at the lumbar spine or femoral neck or a T-score of ՅϪ1.0 and ՆϪ3.5 at the lumbar spine or femoral neck with a prior major osteoporotic fracture and had at least 2 lumbar vertebrae, 1 hip, and 1 forearm evaluable by dual-energy x-ray absorptiometry (DXA). Key exclusion criteria included any severe or Ͼ1 moderate vertebral fracture (using a semiquantitative grading scale) (9), any vertebral fracture or clinical fracture diagnosed within 6 months before screening, diseases that affect bone metabolism, and vitamin D deficiency. Further, men were ineligible if they had received bisphosphonate treatment for 3 months or more cumulatively in the past 2 years, for 1 month or more in the past year, or at any time during the 3-month period before randomization. Men using anabolic steroids or testosterone, glucocorticoids, calcitonin, calcitriol, or vitamin D derivatives and other bone-active drugs in a 3-month period before screening were also excluded. Men with significantly impaired renal function, as determined by a derived glomerular filtration rate (using the Modification of Diet in Renal Disease formula) of Ͻ30 mL/min/1.73 m 2 calculated by a central laboratory, were also excluded.
Study assessments
BMD was assessed by DXA of the lumbar spine, hip, and forearm at screening and at months 6, 12, and 24. DXA scans were performed by a local DXA technologist and were submitted electronically to a central imaging center (Synarc, Inc.) for blinded analysis. All scans for an individual participant were performed on the same scanner (GE Lunar or Hologic bone densitometers). Lateral spine x-rays were performed at screening and at months 12 and 24 and were scored at the central imaging vendor (blinded to treatment allocation) using a semiquantitative grading scale (9) to detect vertebral fractures.
All participants had sCTX (Serum Crosslaps ELISA; IDS Nordic) measured from fasting blood samples drawn at each scheduled visit (except the screening visit) and assessed at the same central laboratory (Covance). Blood samples for assessment of anti-denosumab antibodies were obtained from all participants on day 1 (predose) and at months 12 and 24.
Safety was evaluated by assessing the nature, frequency, severity, relationship to investigational product, and outcome of all AEs, including fractures.
Statistical analyses
For the open-label phase, efficacy was analyzed for all participants who had at least 1 measurement at baseline of the double-blind phase and 1 measurement at a time point during the open-label phase. Observed data were used for the efficacy analyses. The means and 95% confidence intervals of percent changes in BMD from study baseline were estimated at months 12 and 24 using an ANCOVA model with treatment as main effect and minimum baseline BMD T-score (stratification factor) as a covariate. The percent change from months 12 to 24 was descriptive, and a one-sample t test within each treatment arm was performed to assess the significance of change from month 12. Percent changes from baseline in sCTX at each visit were summarized by median and interquartile range, and a sign test within each treatment arm was performed to assess the significance of change from study baseline. No direct statistical comparison was made between the 2 concurrent treatment arms in year 2 or from months 12 to 24.
Safety in the open-label phase was analyzed for all participants who received at least 1 dose of denosumab in the openlabel phase. The crude participant incidence of AEs and exposure-adjusted participant incidence per 100 participant-years were evaluated by treatment group (long-term, crossover) and were descriptive. AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA, version 15.0) coding dictionary. Also summarized were the incidences of all clinical fractures, new vertebral fractures, and clinical osteoporosis-related fractures (defined as a radiological confirmed fracture excluding skull, face, mandible, metacarpals, finger phalanges, toe phalanges, and cervical vertebrae and not associated with high trauma severity or pathologic fracture).
Results
Of the 242 men enrolled and randomly assigned to receive either denosumab (n ϭ 121) or placebo (n ϭ 121) ( Figure 2 Table 1 and were similar to those of the original enrolled cohorts (8) (data not shown). At the beginning of the open-label phase, mean (SD) sCTX in the long-term group was lower (0.17 [0.10] ng/mL), and the BMD T-score was improved, reflecting denosumab administration in the 12-month double-blind phase of the study.
Efficacy
BMD
During the 12-month open-label phase, continued increases in BMD occurred with long-term denosumab treatment at all skeletal sites evaluated (2.2% lumbar spine, 0.9% total hip, 1.3% femoral neck, 1.3% trochan-ter, and 0.2% 1/3 radius) for cumulative gains from baseline to month 24 of 8.0% (lumbar spine), 3.4% (total hip), 3.4% (femoral neck), 4.6% (trochanter), and 0.7% (1/3 radius) (all P Ͻ .01) ( Figure 3 ). The crossover group showed significant gains in BMD at the lumbar spine (4.9%), total hip (1.7%), femoral neck (1.9%), trochanter (2.0%), and 1/3 radius (1.0%) in the open-label phase (all P Յ .0001), similar to those observed in the long-term denosumab group during the first year of treatment (lumbar spine, 5.8%; total hip, 2.3%; femoral neck, 2.2%; trochanter, 3.2%; and 1/3 radius, 0.6%).
Bone turnover markers
For the long-term group, a 60% reduction in sCTX noted in the first phase was observed at month 12 (P Ͻ .0001). At months 18 and 24, sCTX levels remained lower than baseline (57% and 50%, respectively; all P Ͻ .0001) (Figure 4 ). In the crossover group, there was no change in sCTX levels during the first 12-month phase of placebo administration, but during the second 12-month phase of denosumab administration there was a median decrease in sCTX of 68% at month 18 and 59% at month 24 (P Ͻ .0001), a response similar to that observed in the first 12-month phase in denosumab-treated men.
Anti-denosumab antibody assays
Anti-denosumab binding antibodies were not detected at any time point during 24 months of the study (data not shown).
Fractures
During the open-label phase, clinical fractures were reported in 4 men (2 rib and 2 foot) in the long-term denosumab treatment group (3.6%) ( Table 2) . Clinical osteoporotic fractures were reported in 2 men (2 rib) in the The participant incidence of AEs, serious AEs (SAEs), and fatal AEs is summarized in Table 2 . During the open-label phase, the participant incidence of overall AEs was 63% in the long-term group and 52% in the crossover group. Most AEs were mild or moderate in severity in both groups. SAEs occurred in 8.1% of the long-term group and 4.3% of the crossover group. No AEs were reported as serious for Ͼ1 participant in either group. The system organ class with the highest incidence of SAEs was infections and infestations; 5 of 111 men (4.5%) in the long-term group and 1 of 116 (0.9%) in the crossover group. Malignancy AEs were reported in 1 of 111 men (0.9%) in the long-term group (gastric cancer with metastases to the lung) and 2 of 116 men (1.7%) in the crossover group (bladder cancer and malignant lung neoplasm with metastases to central nervous system). The incidence of cardiac disorders, eczema, infections, acute pancreatitis, and AEs potentially associated with hypersensitivity was low and did not appear to increase over time ( Table  2 ). One death caused by bacterial endocarditis was reported in the long-term group; an echocardiogram confirmed mitral valve endocarditis and blood cultures were positive for staphylococcus in a participant without previous valvular disease. There were no reports of hypocalcemia, osteonecrosis of the jaw, fracture healing complications, or atypical femoral fracture. The exposure-adjusted participant inci- (1), malignant lung neoplasm and metastases to central nervous system (1), nodal rhythm (1), and transient ischemic attack (1) . c Arthralgia and infective arthritis (1), atrial fibrillation and pneumonia (1), carotid artery stenosis (1), cholecystitis (1), endocarditis (1), gastric cancer and metastases to lung (1), osteoarthritis (1), pyelonephritis (1), and urosepsis (1). 
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